Cancer therapies have improved dramatically over the last several years, due to the development and discovery of novel therapies resulting from the science and research conducted at AACI cancer centers. Among these are chimeric antigen receptor T-cell (CAR T) therapies. CAR T therapies represent a critical advancement in treating malignancies, and evidence shows these therapies provide important clinical benefits to patients.
The AACI CAR T initiative facilitates collaboration between subject matter experts at AACI’s member centers through webinars, listserv discussions, calls, meetings, and other activities. The steering committee has also submitted comments to the Centers for Medicare & Medicaid Services (CMS) on their proposed national coverage analysis.
The CAR T Initiative Steering Committee helps guide the implementation of CAR T-cell therapy programs at AACI member centers across North America.
Peter Riedell, MD
The University of Chicago Medicine Comprehensive Cancer Center
View All Steering Committee Members